Search results for "rectum"

showing 10 items of 172 documents

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

2014

Abstract Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20–30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection ( RET ) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients. The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methy…

MaleCpg island methylationOncologyCancer Researchmedicine.medical_specialtyColonColorectal cancerBiologyBioinformaticsCell Line TumorInternal medicineGeneticsmedicineHumansStage (cooking)Promoter Regions GeneticneoplasmsResearch ArticlesAgedNeoplasm StagingProportional hazards modelRectumStage II Colorectal CancerPromoterGeneral MedicineMethylationDNA MethylationMiddle AgedPrognosismedicine.diseasedigestive system diseasesOncologyDNA methylationMolecular MedicineCpG IslandsFemaleColorectal NeoplasmsMolecular Oncology
researchProduct

Impact of rectal distension on prostate CBCT-based positioning assessed with 6 degrees-of-freedom couch

2018

International audience; Introduction: Prostate requires a daily correction of its 3-dimensional position in relation with rectal distension. In this study, we sought to determine whether rectal distension with respect to the rectal behavior might have an impact on prostate translations and/or rotations during prostate image guided radiation therapy using a 6 degrees-of-freedom (DOF) couch.Methods and materials: We reviewed the data from 39 patients with localized prostate cancer treated with protracted external radiation therapy using a 6 DOF couch. Before each fraction, a kilovoltage cone beam computed tomography (kV-CBCT) scan was performed. The automatic fusion algorithm was set to fuse …

MaleKilovoltage Cone Beam Computed Tomography[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment78 GyFailureRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineIncreased RiskStandard deviationPatient PositioningTrial030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicineHumansRadiology Nuclear Medicine and imagingConformal Radiation-TherapyImage-guided radiation therapyCancerContouringbusiness.industryImage-GuidanceRadiotherapy Planning Computer-AssistedAcute ToxicityProstateRectumProstatic NeoplasmsRadiotherapy DosageExternal-Beam RadiotherapyCone-Beam Computed Tomographymedicine.diseaseRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisFeasibility StudiesRadiotherapy Intensity-ModulatedStrategiesbusinessNuclear medicineTomography X-Ray ComputedRadiotherapy Image-Guided
researchProduct

An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesore…

2018

Introduction: Transanal total mesorectal excision (TaTME) has rapidly emerged as a novel approach for rectal cancer surgery. Safety profiles are still emerging and more comparative data is urgently needed. This study aimed to compare indications and short-term outcomes of TaTME, open, laparoscopic, and robotic TME internationally. Methods: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients undergoing elective total mesorectal excision (TME) for malignancy between 1 January 2017 and 15 March 2017 by any operative approach were included. The primary outcome measure was anastomotic leak. Results: Of 2579 included patients, 76.2% (1966/257…

MaleLaparoscopic surgerymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentOperative TimeAnastomosisMalignancyrectal cancer ; laparoscopic surgery ; TME ; transanal TME ; TaTME ; robotic surgery ; randomized clinical-trial ; short-term outcomes ; laparoscopic-assisted resection ; pathological outcomes ; anastomotic leakage ; initial-experience ; riskNO03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical Proceduresrobotic surgerytransanal TMEHumansMedicineRobotic surgeryProspective Studieslaparoscopic surgery; Rectal cancer; robotic surgery; TaTME; TME; transanal TME; GastroenterologyRectal cancerAgedTransanal Endoscopic Surgeryta3126Medical AuditUnivariate analysisProctectomyRectal Neoplasmsbusiness.industryRectumGastroenterologyTMEMargins of ExcisionMiddle Agedmedicine.diseaseTotal mesorectal excisionTaTMElaparoscopic surgerySurgeryTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesisRectal cancer surgeryFemaleLaparoscopy030211 gastroenterology & hepatologybusiness
researchProduct

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

2014

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated wi…

MaleMESH: Combined Modality TherapyAnal Carcinomamedicine.medical_treatmentMESH: Lymphatic MetastasisMedical OncologyMESH: Anus Neoplasms0302 clinical medicineDiagnosisSocieties MedicalMESH: Medical Oncologyeducation.field_of_studyIncidence (epidemiology)Follow-upAnal MarginMESH: Carcinoma Squamous CellGeneral MedicineHematologyMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisCombined Modality Therapy3. Good healthmedicine.anatomical_structureOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleRadiologymedicine.medical_specialtyHealth Planning GuidelinesPopulationMESH: Societies MedicalRectumGuidelinesMESH: Prognosis03 medical and health sciencesmedicineAnal cancerHumansRadiology Nuclear Medicine and imagingeducationNeoplasm StagingMESH: Humansbusiness.industryCancerAnusmedicine.diseaseMESH: MaleSurgeryRadiation therapyTreatmentSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieAnal cancerbusinessMESH: FemaleFollow-Up Studies
researchProduct

Exclusion of the Sonic Hedgehog gene as responsible for Currarino syndrome and anorectal malformations with sacral hypodevelopment.

1999

Anorectal malformations (ARMs) are common congenital anomalies that account for 1:4 digestive malformations. ARM patients show different degrees of sacral hypodevelopment while the hemisacrum is characteristic of the Currarino syndrome (CS). Cases of CS present an association of ARM, hemisacrum and presacral mass. A gene responsible for CS has recently been mapped in 7q36. Among the genes localized in this critical region, sonic hedgehog (SHH) was thought to represent a candidate gene for CS as well as for ARM with different levels of sacral hypodevelopment according to its role in the differentiation of midline mesoderm. By linkage analysis we confirmed the critical region in one large fam…

MaleMesodermCandidate geneSacrumAnal CanalPathogenesisGenetic linkageGeneticsmedicineHumansHedgehog ProteinsSonic hedgehogGenetics (clinical)Embryonic InductionbiologyRectumProteinsAnatomySyndromeSacrummedicine.diseaseSonic Hedgehog GenePedigreemedicine.anatomical_structureSettore MED/03 - Genetica Medicabiology.proteinTrans-ActivatorsSettore MED/26 - NeurologiaFemaleDigestive System AbnormalitiesCurrarino syndromeChromosomes Human Pair 7Human genetics
researchProduct

Rectosigmoid Pouch (Mainz Pouch II) in Children

2005

Continent anal urinary diversion is a therapeutic option in bladder exstrophy. We report our long-term results with the rectosigmoid pouch (Mainz pouch II), a modification of the classic ureterosigmoidostomy.A total of 38 children with a mean age of 5 years (range 0.5 to 17) underwent a Mainz pouch II procedure between 1991 and 2004. Most patients (33) had bladder exstrophy or incontinent epispadias. In 14 children (37%) urinary diversion was performed after failed primary reconstruction. In 6 children conversion was performed from an incontinent type of urinary diversion. Renal function, continence and metabolic changes were analyzed. A total of 35 children were followed for a mean of 112 …

MaleNephrologymedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentUrologyUrologyUrineColon SigmoidInternal medicinemedicineHumansChildUpper urinary tractbusiness.industryBladder ExstrophyUrinary Reservoirs ContinentUrinary diversionRectumInfantmedicine.diseaseSurgeryBladder exstrophyStenosisEl NiñoChild PreschoolUrologic Surgical ProceduresFemalePouchbusinessFollow-Up StudiesThe Journal of Urology
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany

2013

Risk of colorectal cancer (CRC) is considerably higher in men compared to women; however, there is inconclusive evidence of sex differences in CRC prognosis. We aimed to assess and explain sex differences in 5-year relative survival using standard and model-based period analysis among 164,996 patients diagnosed with CRC from 1997 to 2006 and reported to 11 German cancer registries covering a population of 33 million inhabitants. Age-adjusted 5-year relative survival was higher in women (64.5% vs. 61.9%, P<0.0001). A substantial survival advantage of women was confirmed in multivariate analysis after adjusting for CRC stage and subsite in subjects under 65 years of age (relative excess ri…

MaleOncologyEpidemiologyColorectal cancerlcsh:MedicineSex hormones ; Cancer detection and diagnosis ; Prognosis ; Colorectal cancer ; Rectum ; Colon ; Germany ; Age groups0302 clinical medicineGermanyRegistriesYoung adultlcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryRelative survivalCancer Risk FactorsColon AdenocarcinomaAge FactorsAbsolute risk reductionMiddle Aged3. Good healthOncologyTransgender hormone therapyPopulation Surveillance030220 oncology & carcinogenesisMedicineFemale030211 gastroenterology & hepatologyColorectal NeoplasmsCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentClinical Research DesignPopulationRectal CancerYoung Adult03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansMortalityeducationBiologyRetrospective StudiesAgedNeoplasm StagingPopulation Biologybusiness.industrylcsh:RCancers and NeoplasmsCancerHormonal Causes of Cancermedicine.diseaseSurgeryLocalized diseaselcsh:QbusinessPLoS ONE
researchProduct

Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Grupp…

2005

BACKGROUND: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance in terms of disease relapse and overall survival has not yet clearly been established. PATIENTS AND METHODS: A prospective study was carried out on paired tumor and normal colon tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective surgery for primary operable sporadic CRC. Mutations within the TP53 (exons 5-8) and Ki-ras (exon 2) genes were detected by PCR-SSCP analyses following sequencing. RESULTS: Mutation analyses of exons 5 to 8 of the TP53 gene showe…

MaleOncologyMultivariate analysisColorectal cancerpolymerase chain reactionmedicine.medical_treatmentLeucovorinColorectal Neoplasmmedicine.disease_causeBioinformaticsExonAntineoplastic Combined Chemotherapy ProtocolsProspective Studiesexongene mutationmultivariate analysiProspective cohort studysingle strand conformation polymorphism MeSH: Adenocarcinomaprotein p53 EMTREE medical terms: adultProto-Oncogene ProteinMutationarticleprotein domainclinical trialHematologyMiddle AgedagedItalypriority journalOncologyChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemaleFluorouracilColorectal Neoplasmscancer tissueprognosiprospective studyHumansamplingmedicine.medical_specialtyfolinic acidgene sequenceAdenocarcinomarectum carcinomaProto-Oncogene Proteins p21(ras)outcomes researchProto-Oncogene ProteinsInternal medicinemedicineHumanscontrolled studyneoplasmsGeneNeoplasm StagingChemotherapyEMTREE drug terms: fluorouracillevamisoleAntineoplastic Combined Chemotherapy Protocolcontrolled clinical trialbusiness.industryfluorouracil; folinic acid; K ras protein; levamisole; protein p53 adult; aged; article; cancer tissue; clinical trial; codon; colon adenocarcinoma; colorectal surgery; controlled clinical trial; controlled study; exon; gene mutation; gene sequence; human; human cell; human tissue; Italy; major clinical study; male; multivariate analysis; oncology; outcomes research; polymerase chain reaction; prediction; priority journal; prognosis; prospective study; protein domain; rectum carcinoma; sampling; sequence analysis; single strand conformation polymorphism Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Levamisole; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Prospective Studies; Proto-Oncogene Proteins; ras Proteins; Tumor Suppressor Protein p53 [EMTREE drug terms]human cellLymphatic Metastasipredictionras Proteinmedicine.diseasemajor clinical studyhuman tissueProto-Oncogene Proteins p21(ras)K ras proteinProspective Studiecolon adenocarcinomaMultivariate AnalysisMutationras Proteinscolorectal surgerysequence analysicodonTumor Suppressor Protein p53businessAnnals of Oncology
researchProduct

High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late, rectal toxicity

2017

PURPOSE: To determine the significance of dose-volume histogram parameters for predicting late rectal toxicity (LRT) after single-fraction high-dose-rate brachytherapy (HDRBT) boost and external beam radiotherapy (EBRT) in prostate cancer. MATERIALS AND METHODS: Three hundred patients with intermediate- or high-risk prostate cancer were included between August 2010 and March 2015. Treatment comprised a single-fraction HDRBT boost of 15.0 Gy plus EBRT (46.0 Gy delivered in 23 fractions) or an HDRBT boost of 9.5 Gy plus EBRT (60.0 Gy delivered in 30 fractions) if the seminal vesicles were infiltrated using real-time transrectal ultrasound-based planning. LRT was evaluated every 3 months after…

MaleOrgans at RiskDose-volume histogramTime Factorsmedicine.medical_treatmentBrachytherapyBrachytherapyRectumLate rectal toxicity030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancerOrgan at risk0302 clinical medicinemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesExternal beam radiotherapyRadiation InjuriesAgedAged 80 and overProstate cancerbusiness.industryRadiotherapy Planning Computer-AssistedBiologically equivalent doseRectumProstatic NeoplasmsCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseaseCombined Modality TherapyHigh-Dose Rate BrachytherapyHigh-dose-rate brachytherapy boostRadiation therapyDose-volume histogram parametermedicine.anatomical_structureOncology030220 oncology & carcinogenesisRegression AnalysisDose Fractionation RadiationNuclear medicinebusinessFollow-Up Studies
researchProduct